睿知中国医院研究地图
候选清单

即将招募淋巴瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 7 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 7

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  2. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  3. 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面
  4. 研究中心上海市第一人民医院Shanghai General Hospital上海医院页面
  5. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  6. 研究中心空军军医大学西京医院Xijing Hospital西安医院页面
  7. 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06970496,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed B-cell non-Hodgkin's lymphoma (B-NHL) with specified pathological subtypes;

    入选标准第 2 条

    Histologically confirmed CD19 and/or CD22 positivity;

    入选标准第 3 条

  3. ECOG performance status 0-1 (Ia) or 0-2 (Ib);

    入选标准第 5 条

  4. At least one measurable lesion in two dimensions according to the Lugano 2014 criteria;

    入选标准第 6 条

  5. Prescribed malignant tumors within 5 years before signing the ICF;

    排除标准第 8 条

  6. Pregnant or breastfeeding women; or male or female subjects who are unwilling to use contraception from the time of signing the ICF until 1 year after receiving B019 injection cell infusion or until CAR is detectable in peripheral blood.;

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06970496,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subjects who can fully understand this trial and voluntarily sign the informed consent form (ICF) before any research-related procedures;
  2. Histologically confirmed B-cell non-Hodgkin's lymphoma (B-NHL) with specified pathological subtypes;
  3. Histologically confirmed CD19 and/or CD22 positivity;
  4. Expected survival time exceeding 12 weeks;
  5. ECOG performance status 0-1 (Ia) or 0-2 (Ib);
  6. At least one measurable lesion in two dimensions according to the Lugano 2014 criteria;
  7. Bone marrow, liver, kidney, and cardiac-pulmonary functions meeting the specified requirements; 8 Subjects who were evaluated by the researchers as tolerant to the collection of peripheral blood mononuclear cells (PBMC); 9 Subjects who were evaluated by the researchers as having no contraindications for lymphodepleting chemotherapy.

排除标准:Exclusion Criteria:

  1. Primary central nervous system (CNS) lymphoma; However, secondary CNS lymphoma without clinical symptoms can be enrolled after being determined by the researchers;
  2. Use of the prescribed drugs or treatments within the specified time before the collection of PBMC;
  3. Prior allogeneic hematopoietic stem cell transplantation;
  4. Systemic intravenous infusion treatment or uncontrollable bacterial, fungal or viral infection within 2 weeks before signing the ICF;
  5. A history of deep vein thrombosis or pulmonary embolism or anticoagulant therapy within 6 months before signing the ICF;
  6. A clinically significant history of severe heart disease within 6 months before signing the ICF;
  7. Terminal organ damage or autoimmune diseases requiring systemic immunosuppressive/systemic treatments within 2 years before signing the ICF; Or have graft-versus-host disease;
  8. Prescribed malignant tumors within 5 years before signing the ICF;
  9. Intestinal obstruction caused by tumor compression or vascular compression requiring emergency treatment; gastrointestinal involvement with a risk of bleeding assessed by the researchers;
  10. Clinically significant CNS diseases in the past or at the time of screening;
  11. A history of severe allergic reactions to the drugs or excipients that were definitely needed in this study. Or have a history of allergic reactions to tocilizumab;
  12. Any indwelling tubes or drainage tubes in the bodies, the use of dedicated central venous access catheters is permitted;
  13. Pregnant or breastfeeding women; or male or female subjects who are unwilling to use contraception from the time of signing the ICF until 1 year after receiving B019 injection cell infusion or until CAR is detectable in peripheral blood.;
  14. The subjects who have participated in other clinical studies within the past 1 month, or whose last medication use for the last clinical study is still within the 5 half-life periods of the current drug at the time of screening;
  15. Other circumstances that the researchers consider unsuitable for participating in this study.

引自 ClinicalTrials.gov, NCT06970496, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06970496,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06970496